OnQuality Announces FDA Clearance of IND Application for OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash
Newsroom
OnQuality Announces FDA Clearance of IND Application for OQL051
OnQuality Announces FDA Clearance of IND Application for OQL036
OnQuality Pharmaceuticals Presented Preclinical Data at the AACR Annual meeting
OnQuality Pharmaceuticals Announces Presentations of OQL025 and OQL06x, at the AACR Annual Meeting
OnQuality Pharmaceuticals Expands Part 2 of the NOVA-II Phase 2 Clinical Trial to China and India
OnQuality Pharmaceuticals Announces Enrollment of First Patient in Part 2 of the NOVA-II Phase 2
OnQuality Pharmaceuticals to Present Two Posters at the 34th EORTC-NCI-AACR Symposium
OnQuality Pharmaceuticals to Have Two Abstracts Published in the 2022 ASCO Annual Meeting Proceeding
OnQuality Pharmaceuticals to Present Preclinical Data for OQL051, a Novel CID Therapeutic, at AACR